Not checkedNot checked for notices yet.
Mild COVID- 19 infection: Do we have any effective drugs? A narrative review
Deependra K Rai, Pramod K Manjhi
Medical Journal of Dr. D.Y. Patil Vidyapeeth · 2022
doi:10.4103/mjdrdypu.mjdrdypu_131_22 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Coronavirus disease (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The clinical spectrum of SARS-CoV-2 infection ranges from asymptomatic infection to critical illness. About 80% of COVID-19 infections are mild or asymptomatic, 15% are associated with severe infection requiring oxygen and 5% are critical infections, requiring ventilation support. Patients with mild illness usually recover at home, with supportive care and isolation. But most of the mild COVID-19 patients have been prescribed off-label medication such as Hydroxychloroquine, Azithromycin, Ivermectin, Doxycycline, Favirapivir, Vitamin C, Vitamin D, an oral and inhaled corticosteroid. Literature showed that the sale of all these medications increased in this pandemic The newer cocktail regimen which is a combination of monoclonal antibody Bamlanivimab and Etesevimab showed very promising results. The newer oral antiviral drug Molnupiravir is also showing very good efficacy in terms of reduction in hospitalization and death. This narrative review looked at evidence regarding each drug for its effect on recovery time, viral clearance, and the risk of progression or hospitalization. Among all these, Ivermectin only shows a promising result. The newer cocktail antibody and antiviral drug Molnupiravir is effective in reducing hospitalization and may be a game changer for the patient with mild-moderate COVID-19 infection. There is a lack of evidence for the use of other drugs in the mild case of COVID 19. Only symptomatic treatment with antipyretic with hydration is enough to combat mild COVID-19 infection.
Abstract licence: CC BY-NC-SA
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.